EA201891597A3 - Bispecific to egfr / c-met antibodies - Google Patents

Bispecific to egfr / c-met antibodies

Info

Publication number
EA201891597A3
EA201891597A3 EA201891597A EA201891597A EA201891597A3 EA 201891597 A3 EA201891597 A3 EA 201891597A3 EA 201891597 A EA201891597 A EA 201891597A EA 201891597 A EA201891597 A EA 201891597A EA 201891597 A3 EA201891597 A3 EA 201891597A3
Authority
EA
Eurasian Patent Office
Prior art keywords
egfr
receptor
bispecific
met antibodies
growth factor
Prior art date
Application number
EA201891597A
Other languages
Russian (ru)
Other versions
EA201891597A2 (en
Inventor
Марк Чиу
Шери Мурс
Йост Нейссен
Пауль Паррен
Янине Схюрман
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201261728912P priority Critical
Priority to US201361782550P priority
Priority to US201361809541P priority
Priority to US201361864717P priority
Priority to US201361892797P priority
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891597(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of EA201891597A2 publication Critical patent/EA201891597A2/en
Publication of EA201891597A3 publication Critical patent/EA201891597A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Abstract

The invention relates to bispecific to EGFR and / or c-Met antibodies and methods for producing and using molecules. The epidermal growth factor receptor (EGFR, ErbB1 or HERI) is a type I 170 kDa transmembrane glycoprotein encoded by the c-ErbB1 proto-oncogene. EGFR is a member of the epidermal growth factor (HER) human receptor family, which are receptor tyrosine kinases (RTKs), including HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). EGFR signaling is initiated by ligand binding, followed by induction of a conformational change, homodimerization or heterodimerization of the receptor with other members of the ErbB family.
EA201891597A 2012-11-21 2013-11-21 Bispecific to egfr / c-met antibodies EA201891597A3 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US201261728912P true 2012-11-21 2012-11-21
US201361782550P true 2013-03-14 2013-03-14
US201361809541P true 2013-04-08 2013-04-08
US201361864717P true 2013-08-12 2013-08-12
US201361892797P true 2013-10-18 2013-10-18

Publications (2)

Publication Number Publication Date
EA201891597A2 EA201891597A2 (en) 2018-12-28
EA201891597A3 true EA201891597A3 (en) 2019-03-29

Family

ID=50728148

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891597A EA201891597A3 (en) 2012-11-21 2013-11-21 Bispecific to egfr / c-met antibodies
EA201590985A EA031184B1 (en) 2012-11-21 2013-11-21 BISPECIFIC EGFR/c-Met ANTIBODIES

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590985A EA031184B1 (en) 2012-11-21 2013-11-21 BISPECIFIC EGFR/c-Met ANTIBODIES

Country Status (25)

Country Link
US (3) US9593164B2 (en)
EP (2) EP3447069A1 (en)
JP (2) JP6423357B2 (en)
KR (1) KR20150087365A (en)
CN (1) CN104955838A (en)
AU (2) AU2013347962B2 (en)
CA (1) CA2893505A1 (en)
CL (1) CL2015001356A1 (en)
DK (1) DK2922872T3 (en)
EA (2) EA201891597A3 (en)
ES (1) ES2700231T3 (en)
HR (1) HRP20182128T1 (en)
HU (1) HUE041499T2 (en)
IL (1) IL238796A (en)
LT (1) LT2922872T (en)
MX (1) MX361088B (en)
NZ (1) NZ708352A (en)
PE (1) PE11812015A1 (en)
PH (1) PH12015501118A1 (en)
PL (1) PL2922872T3 (en)
RS (1) RS58192B1 (en)
SG (1) SG11201503938VA (en)
SI (1) SI2922872T1 (en)
UA (1) UA117121C2 (en)
WO (1) WO2014081954A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602294A (en) 2010-03-10 2015-04-24 Genmab As Monoclonal antibodies against c-met
EP2560993A2 (en) * 2010-04-20 2013-02-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP3057608A4 (en) 2013-10-14 2017-10-11 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
KR20160061199A (en) 2014-11-21 2016-05-31 삼성전자주식회사 Pharmaceutical composition for combination therapy containing dual inhibitor of c-Met and EGFR and IGF-1R inhibitor
EP3240805A4 (en) * 2014-12-15 2018-05-09 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
JP2019500011A (en) * 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Bispecific antibodies with enhanced tumor selectivity and inhibition and uses thereof
KR101985299B1 (en) * 2016-06-03 2019-09-03 삼성전자주식회사 Anti-c-Met/anti-Nrp1 bispecific antibody
EP3471750A2 (en) * 2016-06-21 2019-04-24 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
EP3541423A1 (en) * 2016-11-18 2019-09-25 The Regents of The University of California Engineered antibodies and uses thereof
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
TW201910354A (en) * 2017-08-09 2019-03-16 荷蘭商美勒斯公司 Binding epidermal growth factor receptor (EGFR) antibody and cMET
WO2019040808A1 (en) * 2017-08-25 2019-02-28 Janssen Biotech, Inc. FCγRII BINDING FIBRONECTIN TYPE III DOMAINS, THEIR CONJUGATES AND MULTISPECIFIC MOLECULES COMPRISING THEM
WO2019114793A1 (en) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 Egfr antibody, preparation method therefor and application thereof
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric and humanized antibody against the epidermal growth factor receptor for diagnostic and therapeutic use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド Artificial antibody polypeptides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
PT1392359E (en) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (en) 2001-09-26 2010-12-22 アイシン精機株式会社 Automotive door
AU2003260786B2 (en) 2002-09-06 2008-03-13 Isogenica Limited In vitro peptide expression libraray
BRPI0407446A (en) 2003-02-13 2006-01-31 Pharmacia Corp C-met Antibodies for cancer treatment
KR20110129988A (en) * 2003-07-18 2011-12-02 암젠 인코포레이티드 Specific binding agents to hepatocyte growth factor
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc Antibodies directed to c-MET
WO2005118876A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
DK1773885T3 (en) 2004-08-05 2010-08-16 Genentech Inc Humanized anti-c-met antagonists
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2529790T3 (en) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Methods of treating cancer resistant to therapeutic agents of ERBB
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343595A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. A human non-antibody peptide or protein phage library
EP2231904B1 (en) 2007-12-19 2016-01-13 Janssen Biotech, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CA2716851A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
TW201002346A (en) 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CN102224255A (en) * 2008-08-15 2011-10-19 梅里麦克制药股份有限公司 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
JP2012504606A (en) 2008-10-01 2012-02-23 ラディック インスティテュート フォー キャンサー リサーチ How to treat cancer
CA2741834A1 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CN102361884A (en) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 Bispecific anti-erbb-2/anti-c-met antibodies
ES2708124T3 (en) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedure for preparing heteromultimeric molecules
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DK2506871T3 (en) 2009-11-30 2017-01-02 Janssen Biotech Inc ANTIBODY-Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
NZ602294A (en) * 2010-03-10 2015-04-24 Genmab As Monoclonal antibodies against c-met
EP2560993A2 (en) 2010-04-20 2013-02-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
RS55163B1 (en) 2010-04-30 2017-01-31 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
US9127319B2 (en) * 2010-06-15 2015-09-08 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
KR20140082794A (en) * 2011-10-10 2014-07-02 시티 오브 호프 Meditopes and meditope-binding antibodies and uses thereof
WO2012058768A1 (en) 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN109897103A (en) 2011-11-04 2019-06-18 酵活有限公司 There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
JP6423357B2 (en) 2018-11-14
AU2019200441A1 (en) 2019-02-07
LT2922872T (en) 2018-12-27
US20140255408A1 (en) 2014-09-11
NZ708352A (en) 2019-10-25
ES2700231T3 (en) 2019-02-14
JP2019048817A (en) 2019-03-28
AU2013347962B2 (en) 2018-10-25
SG11201503938VA (en) 2015-06-29
EA201891597A2 (en) 2018-12-28
RS58192B1 (en) 2019-03-29
EP2922872A1 (en) 2015-09-30
EP3447069A1 (en) 2019-02-27
MX361088B (en) 2018-11-26
JP2016505537A (en) 2016-02-25
HUE041499T2 (en) 2019-05-28
US20140141000A1 (en) 2014-05-22
US9580508B2 (en) 2017-02-28
MX2015006387A (en) 2015-12-03
PH12015501118B1 (en) 2016-02-01
HRP20182128T1 (en) 2019-02-08
CL2015001356A1 (en) 2015-11-06
US9593164B2 (en) 2017-03-14
DK2922872T3 (en) 2019-01-02
WO2014081954A1 (en) 2014-05-30
IL238796D0 (en) 2015-06-30
PL2922872T3 (en) 2019-03-29
EP2922872B1 (en) 2018-10-10
SI2922872T1 (en) 2019-01-31
EA201590985A1 (en) 2015-11-30
PH12015501118A1 (en) 2016-02-01
PE11812015A1 (en) 2015-08-19
AU2013347962A1 (en) 2015-05-28
US9695242B2 (en) 2017-07-04
KR20150087365A (en) 2015-07-29
IL238796A (en) 2019-06-30
UA117121C2 (en) 2018-06-25
US20170101475A1 (en) 2017-04-13
CN104955838A (en) 2015-09-30
EP2922872A4 (en) 2016-07-06
EA031184B1 (en) 2018-11-30
CA2893505A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
DK2736895T3 (en) 2- (2,4,5-substituted anilin) -pyrimidine derivatives as egfr modulators used for cancer treatment
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
NZ592215A (en) c-MET ANTIBODIES
NZ718372A (en) Anti-cd134 (ox40) antibodies and uses thereof
EA201170935A1 (en) Methods of obtaining jak kinaz inhibitors and related intermediate compounds
EA028821B9 (en) Compounds and methods for kinase modulation, and indications therefor
ES2571226T3 (en) anti-HER3 antibodies and uses thereof
BR112014031937A2 (en) catalysts comprising salen ligands
HK1207306A1 (en) Modified polynucleotides for the production of proteins associated with human disease
BR112017010591A2 (en) method for preparing a viscose fiber, and viscose fiber
EA201590171A1 (en) IMMUNOCONGATES CONTAINING ANTIBODIES TO CD79b
CU20130023A7 (en) Receptor antibodies 3 epidermal growth factor (HER3)
BRPI0511377A (en) Platinum-resistant cancer treatment methods
EA201201435A1 (en) HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
MX2011009729A (en) Bispecific anti-her antibodies.
RU2015129083A (en) Circle stitching tool with selection of control using the engine and manual control, including the control ring
BR112013027420A2 (en) "Use of genetically modified mice in the preparation of an antibody and method for producing antibodies."
BR112012016818A2 (en) bright colored surface layer
MX2012010019A (en) Antibodies against human csf-1r and uses thereof.
MX2010005856A (en) Anti-vegf antibodies.
WO2005099756A3 (en) ErbB ANTAGONISTS FOR PAIN THERAPY
MX2015006349A (en) Heterodimeric immunoglobulins.
WO2007145862A3 (en) Extending survival of cancer patients with elevated levels of egf or tgf-alpha
RU2012143793A (en) Specific two-valve antibodies anti-vegf / anti-ang-2
MX2013005793A (en) Low affinity blood brain barrier receptor antibodies and uses therefor.